Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore

E. David Crawford hosts a discussion with Neal Shore and Jehonathan Pinthus on the adverse effects of androgen deprivation therapy (ADT).  Viewers will gain knowledge on the optimal role of the antagonist vs agonist and a closer look at adverse effects of ADT and recommendations for patients undergoing ADT.  The notion of sarcopenia and recommendations in fitness and strength training to reduce risk of fracture, improve quality of life and better tolerate other therapies are explained.  Also, discussed is the controversey of dementia and ADT and its increase prevalence.  Dr. Shore explains the concept of therapeutic layering and the future of this field referencing the RADAR 11 study. In addition, Dr. Pinthus discusses results from the RADICAL PC trial and cardiovascular risks with ADT.  (length of lecture: 38 minutes)

Related content:
Watch Jehonathan Pinthus on: ADT Impact on Cardiovascular Health 

AUA 2017: Cardiovascular Disease Characteristics of Newly Diagnosed Prostate Cancer Patients: Findings from the Pilot Phase of Radical PC: A Prospective Study of Cardiovascular Disease in Men with Prostate Cancer

Watch Thomas Keane discuss: Bones, Hot Flashes and ADT: Using with Chemotherapy and Timing

Biographies:

Jehonathan H. Pinthus, MD, PhD, FRCSC is a surgical oncologist-urologist and ssociate Professor in the Department of Surgery Division of Urology McMaster University. He is heading a basic and translational research laboratory at McMaster University and his research interests relates to the patients individual host factors and metabolism that affects prostate cancer growth and response to therapy. Dr. Pinthus is the principle investigator on many research grants the most recent one being the Movember-Prostate Cancer Canada grant titled "Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC)" to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease. 

E. David Crawford, MD